GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax
Executive Summary
The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.
You may also be interested in...
Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk
GlaxoSmithKline's vaccine has 97.16% efficacy, surpassing Merck's Zostavax, but US advisory committee will weigh risks from inflammation which could cause ocular adverse effects and gout.
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.
GSK Files Blockbuster Hopeful Shingrix With FDA
The shingles vaccine is considered one of the products with the biggest commercial potential for GSK in the near-term.